Editor's Pick: Markets: The week that was (16-20/11/09)
(SUMM.L) Summit Corporation PLC Buy/Sell
Add to portfolio Set Alert Level 2 Desktop Trader
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Date/Time | Headline | Source |
|---|---|---|
| 09-11-09 | HUG |
|
|
Holding(s) in Company Summit Corporation plc ("Summit plc" or "the Company")
HOLDINGS IN SUMMIT CORPORATION PLC TR-1: Notification of Major Interests in Shares 9 November 2009, Oxford, UK 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Summit Corporation Plc 2. Reason for notification (yes/no) An acquisition or disposal of voting rights: Yes An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to notification obligation: Barclays PLC 4. Full name of shareholder(s) (if different from 3): Barclays Stockbrokers Ltd 5. Date of transaction (and date on which the threshold is crossed or reached if different): 4 November 2009 6. Date on which issuer notified: 5 November 2009 7.Threshold(s) that is/are crossed or reached: 7% to 6% 8: Notified Details A: Voting rights attached to shares
+-------------------------------------------------------------------------------------------+
|Class/type of|Situation previous to |Resulting situation after the triggering transaction|
| |------------------------+----------------------------------------------------|
|-------------+----------+-------------+-----------+--------+----------+---------+----------|
+-------------------------------------------------------------------------------------------+ B:Financial Instruments
+------------------------------------------------------------------------------+
|------------------------------------------------------------------------------|
|Type of |Expiration|Exercise/Conversion|Number of voting rights that |% of |
|----------+----------+-------------------+-----------------------------+------|
+------------------------------------------------------------------------------+ C: Financial Instruments with similar economic effects to Qualifying Financial Instruments
+--------------------------------------------------------------------------------+
|--------------------------------------------------------------------------------|
|Type of |Exercise|Expiration|Exercise/ |Number of voting rights |% of voting |
|----------+--------+----------+----------+------------------------+-------------|
|----------+--------+----------+----------+------------------------+-------+-----|
+--------------------------------------------------------------------------------+ Total (A+B+C)
+----------------------------------------------+
| Number of voting rights | % of voting rights |
|-------------------------+--------------------|
+----------------------------------------------+ 9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable: Barclays Stockbrokers Ltd Proxy Voting: 10. Name of proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: 13. Additional information: 14. Contact name: Geoff Smith 15. Contact telephone name: 020 7116 2913
---END OF MESSAGE--- This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement. More |
||
| 06-11-09 | HUG |
|
|
Holding(s) in Company Summit Corporation plc ("Summit plc" or "the Company")
HOLDINGS IN SUMMIT CORPORATION PLC TR-1: Notification of Major Interests in Shares 6 November 2009, Oxford, UK 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Summit Corporation Plc 2. Reason for notification (yes/no) An acquisition or disposal of voting rights: Yes An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to notification obligation: Barclays PLC 4. Full name of shareholder(s) (if different from 3): Barclays Stockbrokers Ltd 5. Date of transaction (and date on which the threshold is crossed or reached if different): 3 November 2009 6. Date on which issuer notified: 4 November 2009 7.Threshold(s) that is/are crossed or reached: 6% to 7% 8: Notified Details A: Voting rights attached to shares
+-------------------------------------------------------------------------------------------+
|Class/type of|Situation previous to |Resulting situation after the triggering transaction|
| |------------------------+----------------------------------------------------|
|-------------+----------+-------------+-----------+--------+----------+---------+----------|
+-------------------------------------------------------------------------------------------+ B:Financial Instruments
+------------------------------------------------------------------------------+
|------------------------------------------------------------------------------|
|Type of |Expiration|Exercise/Conversion|Number of voting rights that |% of |
|----------+----------+-------------------+-----------------------------+------|
+------------------------------------------------------------------------------+ C: Financial Instruments with similar economic effects to Qualifying Financial Instruments
+--------------------------------------------------------------------------------+
|--------------------------------------------------------------------------------|
|Type of |Exercise|Expiration|Exercise/ |Number of voting rights |% of voting |
|----------+--------+----------+----------+------------------------+-------------|
|----------+--------+----------+----------+------------------------+-------+-----|
+--------------------------------------------------------------------------------+ Total (A+B+C)
+----------------------------------------------+
| Number of voting rights | % of voting rights |
|-------------------------+--------------------|
+----------------------------------------------+ 9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable: Barclays Stockbrokers Ltd Proxy Voting: 10. Name of proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: 13. Additional information: 14. Contact name: Geoff Smith 15. Contact telephone name: 020 7116 2913
---END OF MESSAGE--- This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement. More |
||
| 03-11-09 | HUG |
|
|
Holding(s) in Company Summit Corporation plc ("Summit plc" or "the Company")
HOLDINGS IN SUMMIT CORPORATION PLC TR-1: Notification of Major Interests in Shares 3 November 2009, Oxford, UK 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Summit Corporation Plc 2. Reason for notification (yes/no) An acquisition or disposal of voting rights: Yes An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to notification obligation: IP Group plc 4. Full name of shareholder(s) (if different from 3): IP2IPO Limited 5. Date of transaction (and date on which the threshold is crossed or reached if different): 2 November 2009 6. Date on which issuer notified: 3 November 2009 7.Threshold(s) that is/are crossed or reached: Below 3% 8: Notified Details A: Voting rights attached to shares
+---------------------------------------------------------------------------------------+
| |---------------------------+---------------------------------------------|
|-------------+----------+----------------+--------+--------+--------+---------+--------|
+---------------------------------------------------------------------------------------+ B:Financial Instruments
+------------------------------------------------------------------------------+
|------------------------------------------------------------------------------|
|Type of |Expiration|Exercise/Conversion|Number of voting rights that |% of |
|----------+----------+-------------------+-----------------------------+------|
+------------------------------------------------------------------------------+ C: Financial Instruments with similar economic effects to Qualifying Financial Instruments
+--------------------------------------------------------------------------------+
|--------------------------------------------------------------------------------|
|Type of |Exercise|Expiration|Exercise/ |Number of voting rights |% of voting |
|----------+--------+----------+----------+------------------------+-------------|
|----------+--------+----------+----------+------------------------+-------+-----|
+--------------------------------------------------------------------------------+ Total (A+B+C)
+----------------------------------------------+
| Number of voting rights | % of voting rights |
|-------------------------+--------------------|
+----------------------------------------------+ 9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable: Proxy Voting: 10. Name of proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: 13. Additional information: IP2IPO Limited is a wholly owned subsidiary of IP Group plc 14. Contact name: Greg Smith 15. Contact telephone name: 0207 4440050
---END OF MESSAGE--- This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement. More |
||
| 02-11-09 | HUG |
|
|
Director/PDMR Shareholding Summit Corporation plc ("Summit" or "the Company") DIRECTOR AND PDMR DEALINGS: PURCHASE OF SHARES Oxford, UK, 2 November 2009 - Summit Corporation plc (AIM: SUMM) today announces the purchase of Summit one pence Ordinary shares by the following Directors and PDMRs:
+------------------------------------------------------------------------+
|----------+-----------------------+---------+---------+---------+-------|
|----------+-----------------------+---------+---------+---------+-------|
|----------+-----------------------+---------+---------+---------+-------|
|----------+-----------------------+---------+---------+---------+-------|
|----------+-----------------------+---------+---------+---------+-------|
|----------+-----------------------+---------+---------+---------+-------|
+------------------------------------------------------------------------+ In addition, the Company's Senior Director of Research & Development, Jon Tinsley, PhD and Senior Director of Strategic Alliances, David Williams, PhD have purchased today a combined total of 200,000 one pence Ordinary shares in the business at a price of 5.5 pence and 50,000 one pence Ordinary shares at a price of 6.0 pence.
-- ENDS - For more information, please contact: Summit plc Steven Lee, PhD Richard Pye, PhD Tel: +44 (0)1235 443939 Panmure Gordon Andrew Burnett / Rakesh Sharma (Corporate Finance) Ashton Clanfield (Corporate Broking) Tel: +44 (0)207 459 3600 About Summit plc Summit plc is a UK based drug discovery company with a major focus on developing new therapeutics from its iminosugar drug discovery platform. Summit believes iminosugars are the key to gaining access to several disease mechanisms where classical drug candidates have had little success, and therefore offer a major opportunity for the discovery and development of new medicines. Carbohydrates play critical roles in maintaining correct function of many normal processes in healthy individuals and provide a wealth of new targets for drug discovery. Iminosugars have the capability of accessing such targets and offer the potential of generating new medicines in a variety of major therapy areas. Summit is currently focussed on metabolic diseases, including diabetes, and anti-virals. Commercially, Summit has a track record of signing programme agreements and currently has an out-licensed product portfolio comprising of seven drug programmes with BioMarin, Orient Pharma, Evolva and the Lilly TB Drug Discovery Initiative. In the future these programmes may generate success based milestone payments and royalties for Summit. The company listed on the alternative investment market (AIM) of the London Stock Exchange in October 2004 - symbol: SUMM. Further information about the company is available at www.summitplc.com. This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.
---END OF MESSAGE--- This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement. More |
||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| Wed 19:00 | ||||
|
| ||||
|
| ||||
|
Yep agreed. Patience is needed here. I have filed this investment in the bottom drawer in a folder marked 'slow roast for 6 months'
More | View thread (3) | Respond | Login to Vote up | Login to Vote down |
||||
| Wed 18:43 | ||||
|
| ||||
|
| ||||
|
Keep ye hat on, news will come and all in at 6p or below will have at least a 3 bagger on there hands, mmm lovely.
To keep ye frustrations down have a few tonight on me. I am sure the way things are going we will see some good news and 20p we will be, hang on feller. Best Regards pop up More | View thread (3) | Respond | Login to Vote up | Login to Vote down |
||||
| Wed 17:35 | ||||
|
| ||||
|
| ||||
|
It's about time we heard SOMETHING - Director buys are all well and good, but where's the news? Come on BOD tell us what's happening please??
More | View thread (3) | Respond | Login to Vote up | Login to Vote down |
||||
| 13-11-09 | ||||
|
| ||||
|
| ||||
|
With you on that - anything in the low 6's must be worth a punt given directors/staff purchases.
More | View thread (3) | Respond | Login to Vote up | Login to Vote down |
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Discussion Board Terms & Conditions FSA Market Abuse Fact Sheet
More...